Lidocaine treatment of painful diabetic neuropathy and endogenous opioid peptides in plasma.

Abstract

Intravenous infusion of lidocaine has a pain-relieving effect in patients with painful diabetic neuropathy. We measured plasma beta-endorphin (beta-EP), dynorphin immunoreactivity (DYN), and met-enkephalin (MET) before and after lidocaine infusion in 8 patients with painful diabetic neuropathy and in 10 controls. The pretreatment level of beta-EP and DYN was identical in the two groups. After lidocaine, beta-EP increased in diabetic patients from 3.4 to 5.5 pmol/L (median) (p less than 0.02) and in controls from 3.4 to 5.0 pmol/L (p less than 0.02). The concentration of DYN was stable, and MET was undetectable before and after lidocaine. Lidocaine reduced symptoms and pain score in diabetic patients was uncorrelated with the changes in beta-EP. Intravenous lidocaine increased plasma beta-EP and diminished complaints in patients with painful diabetic neuropathy.

Cite this paper

@article{Kastrup1989LidocaineTO, title={Lidocaine treatment of painful diabetic neuropathy and endogenous opioid peptides in plasma.}, author={Jens Kastrup and Flemming Winther Bach and Per Hyltoft Petersen and A. Dejg{\aa}rd and Rolf Ekman and Susi Jensen and Helle Riis Angelo}, journal={The Clinical journal of pain}, year={1989}, volume={5 3}, pages={239-44} }